191 related articles for article (PubMed ID: 38016720)
1. High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy.
Han D; Han Y; Guo W; Wei W; Yang S; Xiang J; Che J; Zhu L; Hang J; van den Ende T; van Laarhoven HWM; Li B; Ye Y; Li H
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38016720
[TBL] [Abstract][Full Text] [Related]
2. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.
Wang X; Ling X; Wang C; Zhang J; Yang Y; Jiang H; Xin Y; Zhang L; Liang H; Fang C; Zheng D; Zhu J; Ma J
Cancer Immunol Immunother; 2023 Jun; 72(6):1619-1631. PubMed ID: 36583750
[TBL] [Abstract][Full Text] [Related]
3. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Zheng DD; Li YY; Yuan XY; Lu JL; Zhang MF; Fu J; Zhang CZ
BMC Cancer; 2024 May; 24(1):649. PubMed ID: 38802821
[TBL] [Abstract][Full Text] [Related]
4. PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma.
Liu J; Chen H; Qiao G; Zhang JT; Zhang S; Zhu C; Chen Y; Tang J; Li W; Wang S; Tian H; Chen Z; Ma D; Tian J; Wu YL
Cancer Immunol Immunother; 2023 Apr; 72(4):881-893. PubMed ID: 36121452
[TBL] [Abstract][Full Text] [Related]
5. Immunological Responses Associated With Neoadjuvant Therapy in the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma.
Takehara Y; Tamaki T; Mimura K; Saito K; Neupane P; Tada T; Watanabe Y; Hayase S; Saze Z; Yoshimoto Y; Sato H; Kono K; Suzuki Y
Anticancer Res; 2023 Oct; 43(10):4691-4700. PubMed ID: 37772585
[TBL] [Abstract][Full Text] [Related]
6. Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma.
Wen J; Fang S; Hu Y; Xi M; Weng Z; Pan C; Luo K; Ling Y; Lai R; Xie X; Lin X; Lin T; Chen J; Liu Q; Fu J; Yang H
EBioMedicine; 2022 Dec; 86():104371. PubMed ID: 36434949
[TBL] [Abstract][Full Text] [Related]
7. The single cell immunogenomic landscape after neoadjuvant immunotherapy combined chemotherapy in esophageal squamous cell carcinoma.
Wang Z; Zhao Y; Wo Y; Peng Y; Hu W; Wu Z; Liu P; Shang Y; Liu C; Chen X; Huang K; Chen Y; Hong H; Li F; Sun Y
Cancer Lett; 2024 Jul; 593():216951. PubMed ID: 38734159
[TBL] [Abstract][Full Text] [Related]
8. A tumor immune microenvironment-related integrated signature can predict the pathological response and prognosis of esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A multicenter study in China.
Wu P; Zhang Z; Yuan Y; Zhang C; Zhang G; Xue L; Yang H; Wang L; Zheng X; Zhang Y; Yuan Y; Lei R; Yang Z; Zheng B; Xue Q; Sun N; He J
Int J Surg; 2022 Nov; 107():106960. PubMed ID: 36257585
[TBL] [Abstract][Full Text] [Related]
9. Progenitor-like exhausted SPRY1
Liu Z; Zhang Y; Ma N; Yang Y; Ma Y; Wang F; Wang Y; Wei J; Chen H; Tartarone A; Velotta JB; Dayyani F; Gabriel E; Wakefield CJ; Kidane B; Carbonelli C; Long L; Liu Z; Su J; Li Z
Cancer Cell; 2023 Nov; 41(11):1852-1870.e9. PubMed ID: 37832554
[TBL] [Abstract][Full Text] [Related]
10. PES1 reduces CD8
Ma N; Hua R; Yang Y; Liu ZC; Pan J; Yu BY; Sun YF; Xie D; Wang Y; Li ZG
J Biomed Sci; 2023 Mar; 30(1):20. PubMed ID: 36959575
[TBL] [Abstract][Full Text] [Related]
11. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.
Park S; Joung JG; Min YW; Nam JY; Ryu D; Oh D; Park WY; Lee SH; Choi Y; Ahn JS; Ahn MJ; Park K; Sun JM
J Immunother Cancer; 2019 May; 7(1):128. PubMed ID: 31097034
[TBL] [Abstract][Full Text] [Related]
12. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
Fukuoka E; Yamashita K; Tanaka T; Sawada R; Sugita Y; Arimoto A; Fujita M; Takiguchi G; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
Anticancer Res; 2019 Aug; 39(8):4539-4548. PubMed ID: 31366557
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
15. The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma.
Tsuchikawa T; Miyamoto M; Yamamura Y; Shichinohe T; Hirano S; Kondo S
Ann Surg Oncol; 2012 May; 19(5):1713-9. PubMed ID: 21822560
[TBL] [Abstract][Full Text] [Related]
16. Transcription factor RUNX3 promotes CD8
Song Q; Shang J; Zhang C; Chen J; Zhang L; Wu X
J Cell Biochem; 2020 Jun; 121(5-6):3208-3220. PubMed ID: 31898342
[TBL] [Abstract][Full Text] [Related]
17. COL19A1 is a predictive biomarker for the responsiveness of esophageal squamous cell carcinoma patients to immune checkpoint therapy.
Liu JH; Lin JZ; Qiu Q; Zhu C; Li W; Li Q; Huang Z; Xia X; Qiao G; Tang J
Thorac Cancer; 2023 May; 14(14):1294-1305. PubMed ID: 37005910
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA Regulating ImMune Escape regulates mixed lineage leukaemia protein-1-H3K4me3-mediated immune escape in oesophageal squamous cell carcinoma.
Liu J; Zhou WY; Luo XJ; Chen YX; Wong CW; Liu ZX; Bo Zheng J; Yu Mo H; Chen JQ; Li JJ; Zhong M; Xu YH; Zhang QH; Pu HY; Wu QN; Jin Y; Wang ZX; Xu RH; Luo HY
Clin Transl Med; 2023 Sep; 13(9):e1410. PubMed ID: 37712124
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis of bulk and single-cell gene expression profiles to identify tumor-associated macrophage-derived CCL18 as a therapeutic target of esophageal squamous cell carcinoma.
Sui X; Chen C; Zhou X; Wen X; Shi C; Chen G; Liu J; He Z; Yao Y; Li Y; Gao Y
J Exp Clin Cancer Res; 2023 Feb; 42(1):51. PubMed ID: 36850011
[TBL] [Abstract][Full Text] [Related]
20. Risk model based on genes regulating the response of tumor cells to T-cell-mediated killing in esophageal squamous cell carcinoma.
Zhang X; Yu C; Zhou S; Zhang Y; Tian B; Bian Y; Wang W; Lin H; Wang LW
Aging (Albany NY); 2024 Feb; 16(3):2494-2516. PubMed ID: 38305770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
